DIRS.INFO The most relevant business & tech news

The Summary Studies have found that wildfire smoke negatively affects brain health. “A lot of the research on wildfire smoke has historically focused on our lungs and our hearts,” said Stephanie Cleland, an assistant professor at Simon Fraser University who studies the health impacts of wildfire smoke. Scientists think the reason wildfire smoke affects the brain is that the tiny particles within it can cross the barrier between the bloodstream and the brain, causing inflammation in the central nervous system. Other research published the same year showed that exposure to wildfire smoke during the school year reduced students’ test scores relative to a year with no smoke. “Last summer completely changed our conversation around who’s exposed to wildfire smoke,” she said.

Persons: ”, Stephanie Cleland, Holly Elser, Cleland, Marshall Burke, ” Burke, ” Elser, “, Elser, it’s, who’s Organizations: Simon Fraser University, Alzheimer’s Association International Conference, Hospital of, University of Pennsylvania, Stanford University Locations: California , Oregon, Montana, Northern, Southern California, U.S, Midwest, “ Oregon, California, Washington, British Columbia, Northeast U.S, Ontario

☆ Replacing red meat cuts dementia risk by 20%, study says
▼ + stars: | 2024-07-31 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

The risk for dementia dropped by 20%, however, for people who replaced that small daily serving of processed red meat with a daily serving of nuts and legumes. Processed red meats such as bacon, sausage, hot dogs and deli meats often contain higher levels of sodium, nitrates and saturated fat. Each additional serving of processed red meat raised riskAn abstract of the study, which is under review for publication, was presented Wednesday at the 2024 Alzheimer’s Association International Conference in Philadelphia. Red meat intake is limited. Red meat, especially processed red meat as seen here, is linked to an unhealthy heart and brain.

Persons: ”, Walter Willett, ” Willett, David Katz, Katz, Maria Carrillo, Tanja Ivanova, Yuhan Li, Li, Christopher Gardner, ” Gardner, chia, sprinkle chia Organizations: CNN, Harvard, of Public Health, True Health Initiative, International Conference, Nurses, Alzheimer’s Association, Getty, Division, Network Medicine, Brigham, Women’s Hospital, Stanford Prevention Research, Nutrition Studies Research Locations: Chan, Boston, Philadelphia, bologna, lima, California

☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
▼ + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.

Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish

☆ Shingles vaccines may reduce dementia risk, two large new studies suggest
▼ + stars: | 2024-07-30 | by ( Brenda Goodman | ) edition.cnn.com time to read: +9 min

In 2017, a stronger vaccine, Shingrix, became available. “While research into whether vaccines affect dementia risk continues, people should be aware that there are other factors that have definitively been linked to an increased dementia risk. This study also found that the new shingles vaccine was associated with a larger degree of benefit than the older one. Although the findings are intriguing, the association needs more study before researchers can know for sure that the shingles vaccine is definitively behind the benefit. So for the time being, the best reason to get a shingles vaccine is still to avoid the misery of shingles.

Persons: stow, Shingrix, that’s, ”, Paul Harrison, ” Harrison, Dr, Andrew Doig, ” Doig, it’s, Sheona Scales, Scales, Sanjay Gupta, Phil Dormitzer Organizations: CNN, US Centers for Disease Control, Nature, GlaxoSmithKline, GSK, University of Oxford, University of Manchester, Alzheimer’s Research, Alzheimer’s Association International Conference, Oxford, CNN Health Locations: United States

☆ Long-term exposure to wildfire smoke linked to increased risk of dementia diagnosis, new study finds
▼ + stars: | 2024-07-29 | by ( Maya Davis | ) edition.cnn.com time to read: +6 min

The researchers measured the impact of PM2.5 - air pollution particles that are 2.5 microns or smaller in diameter – from wildfire smoke as well as other sources, such as motor vehicles and factories. The research also indicates that associations between wildfire smoke and dementia diagnoses are most pronounced among people from racially and ethnically minoritized groups and in high-poverty areas. What you can doIndividuals can protect themselves from air pollution, including wildfire smoke, by staying indoors on poor air quality days. Home air filtration systems, including box fan air circulation, can also significantly improve indoor air quality, she said. “Our paper underscores that [wildfire smoke] is potentially an important one for individual patients and their providers who are who are curious what steps they can take.”

Persons: ”, Holly Elser, Maria Carrillo, they’ll, ” Elser, Dr, Sanjay Gupta, Carillo, there’s Organizations: CNN, International Conference, University of Pennsylvania, Alzheimer’s Association, Western, Get CNN, CNN Health Locations: Southern California, California, Canada, Greece, Western United States, Hawaii

☆ Alzheimer’s blood test catches 90% of early dementia cases, study finds
▼ + stars: | 2024-07-28 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +10 min

CNN —A combined blood test for cognitive decline has a 90% accuracy rate in determining whether memory loss is due to Alzheimer’s disease, a new study found. “The p-tau217 blood test is turning out to be the most specific for Alzheimer’s and the one with the most validity. “These are absolutely transformational times.”How does a p-tau217 blood test work? The results of the blood tests were then measured against patient diagnoses provided by Swedish primary care doctors and specialists. “There’s no one more bullish on these tests than I am, but Alzheimer’s blood tests aren’t fully definitive yet,” he said.

Persons: CNN —, Sebastian Palmqvist, ” Palmqvist, ”, Maria Carrillo, Carrillo, “ You’re, that’s, ” Carrillo, “, ” Tau tangles, Richard Isaacson, Oskar Hansson, ” Hansson, Hansson, Isaacson, ” Isaacson Organizations: CNN, Lund University, “, Alzheimer’s Association, International Conference Locations: Sweden, Alzheimer’s, Florida, United States, Philadelphia

☆ In new criteria for Alzheimer’s, some see much-needed progress while others fear profit may be driving ‘diagnostic creep’
▼ + stars: | 2024-07-01 | by ( Brenda Goodman | ) edition.cnn.com time to read: +12 min

CNN —With another pricey Alzheimer’s disease treatment expected to receive an approval decision soon, the nonprofit Alzheimer’s Association has published the final version of its new diagnostic criteria for the disease. Together with another protein, tau, which makes fibrous tangles that block the communication of nerve cells, they are considered a hallmark of Alzheimer’s disease. “There’s no evidence for it,” said Dr. George Perry, a neurobiologist and editor of the Journal of Alzheimer’s Disease. Two members of the panel were employees of the Alzheimer’s Association, which also takes funding from pharmaceutical companies. Widera says he hopes that in the next round of guidelines, the Alzheimer’s Association will consider the risks involved.

Persons: There’s, –, donanemab, “, ”, George Perry, Adriane Fugh, Berman, haven’t, Maria C, Carrillo, Alzheimer’s, It’s, Eric Widera, Widera, it’s, Aduhelm, Karl Herrup, Clifford Jack, ” Jack, “ It’s, Niles Franz, ” Franz, Dr, Sanjay Gupta, Franz, ” Widera Organizations: CNN, Alzheimer’s Association, Food and Drug Administration, FDA, Georgetown University, University of California San, American Geriatrics Society, Abbott Labs, University of Pittsburgh School of Medicine, Mayo Clinic, Nature Medicine, federal National Institute, Aging, Alzheimer’s Association International, National Institute, National Institutes of Health, NIA, Alzheimer’s, National Academy of Medicine, CNN Health, Association Locations: University of California San Francisco

☆ Doubts abound about a new Alzheimer’s blood test
▼ + stars: | 2023-10-18 | by ( Judith Graham | ) edition.cnn.com time to read: +10 min

The Quest Diagnostics blood test, AD-Detect, measures elevated levels of amyloid-beta proteins, a signature characteristic of Alzheimer’s. But Alzheimer’s researchers and clinicians aren’t convinced the Quest test is backed by sound scientific research. Though blood tests for Alzheimer’s are likely to become common in the years ahead, the Alzheimer’s Association said it’s premature to offer a test of this kind directly to consumers. Because the science behind blood tests for Alzheimer’s is still developing and because “patients may not really understand the uncertainty of test results,” Edelmayer said, the Alzheimer’s Association “does not endorse the use of the AD-Detect test by consumers.”Quest’s blood test is one of several developments altering the landscape of Alzheimer’s care in the United States. The bottom line: Before taking a test, “older adults need to ask themselves, ‘Why do I want to know this?

Persons: aren’t, Alzheimer’s, Michael Racke, ”, there’s, Suzanne Schindler, St . Louis, That’s, ” Schindler, Racke, Meera Sheffrin, —, Rebecca Edelmayer, ” Edelmayer, Eric Widera, Dr, Sanjay Gupta, Emily Largent, ’ ”, Munro Cullum Organizations: Health, Diagnostics, Alzheimer’s Association, Quest, University of Michigan, International Conference, Washington University School of Medicine, Senior, Stanford Healthcare, The University of Michigan, FDA, National Institute, Aging, University of California, Get CNN, CNN Health, University, Pennsylvania’s Perelman, of Medicine, HIPAA, University of Texas Southwestern Medical Center, Kaiser Health, KFF Locations: U.S, San Diego, St ., United States, San Francisco

☆ Volunteering in late life may protect the brain, research finds
▼ + stars: | 2023-07-20 | by ( Kristen Rogers | ) edition.cnn.com time to read: +6 min

New research backs her up: Volunteering has been linked with better scores on tests of cognitive function, according to research presented Thursday at the Alzheimer’s Association International Conference in Amsterdam. “We hope these new data encourage individuals of all ages and backgrounds to engage in local volunteering — not only to benefit their communities, but potentially their own cognitive and brain health.”Previous studies have found positive links between volunteering and cognitive function. These adults were around age 74 on average and had participated in the Kaiser Healthy Aging and Diverse Life Experiences Study or the Study of Healthy Aging in African Americans. Barberena thinks volunteering helps maintain her cognition by engaging her memory, verbal and reasoning skills, she said. Previous studies have found socializing and physical activity, both often involved in volunteering, to be beneficial for brain health.

Persons: Celia Barberena, Barberena, ”, “, Donna McCullough, —, it’s, Maria C, Carrillo, wasn’t, hadn’t, ” Carrillo, Yi Lor, Lor, ” Barberena, ” Lor Organizations: CNN, Alzheimer’s Association International, “ Volunteers, Alzheimer’s Association, Healthy Aging, Aging, University of California, Alliance Locations: Latina, Pacific Grove , California, Amsterdam, Davis, Monterey County, “, California’s Monterey

☆ Constipation linked with cognitive decline, research finds
▼ + stars: | 2023-07-19 | by ( Kristen Rogers | ) edition.cnn.com time to read: +6 min

Chronic constipation has been linked with inflammation and mental disorders such as anxiety and depression, but there have been many unanswered questions about the relationship between digestive health and long-term cognitive function, according to a news release. Cognitive function refers to a person’s mental capacity for learning, thinking, reasoning, problem-solving, decision-making, remembering and paying attention. To find clues to these queries, the authors assessed more than 112,000 adults who had participated in the Nurses’ Health Study, Nurses’ Health Study II and Health Professionals Follow-Up Study. The authors of the latest research collected data on participants’ bowel movement frequency from 2012 to 2013, participants’ self-assessments of cognitive function between 2014 and 2017, and details on some participants’ objectively measured cognitive function between 2014 and 2018. But bowel movement frequency and subjective cognitive function were also linked with the participants’ gut microbiomes, the authors found.

Persons: ”, Chaoran Ma, pooped, Maria C, Carrillo, wasn’t, “, ” Ma, Butyrates, Ruminococcus, ” Carrillo Organizations: CNN, Alzheimer’s Association International, University of Massachusetts Amherst, Nurses, Health, Alzheimer’s Association, Cleveland Clinic, Food and Drug Administration Locations: Amsterdam, “, North America

☆ Treating Alzheimer’s Very Early Offers Better Hope of Slowing Decline, Study Finds
▼ + stars: | 2023-07-17 | by ( Pam Belluck | More About Pam Belluck | ) www.nytimes.com time to read: +1 min

Treating Alzheimer’s patients as early as possible — when symptoms and brain pathology are mildest — provides a better chance of slowing cognitive decline, a large study of an experimental Alzheimer’s drug presented Monday suggests. The study of 1,736 patients reported that the drug, donanemab, made by Eli Lilly, can modestly slow the progression of memory and thinking problems in early stages of Alzheimer’s, and that the slowing was greatest for early-stage patients when they had less of a protein that creates tangles in the brain. For people at that earlier stage, donanemab appeared to slow decline in memory and thinking by about four and a half to seven and a half months over an 18-month period compared with those taking a placebo, according to the study, published in the journal JAMA. Among people with less of the protein, called tau, slowing was most pronounced in those younger than 75 and those who did not yet have Alzheimer’s but had a pre-Alzheimer’s condition called mild cognitive impairment, according to data presented Monday at the Alzheimer’s Association International Conference in Amsterdam. “The earlier you can get in there, the more you can impact it before they’ve already declined and they’re on this fast slope,” Dr. Daniel Skovronsky, Eli Lilly’s chief medical and scientific officer, said in an interview.

Persons: Eli Lilly, donanemab, “, they’ve, Dr, Daniel Skovronsky, Eli Lilly’s Organizations: Alzheimer’s Association International Locations: Amsterdam

☆ Second Alzheimer’s drug to slow disease’s progression may be approved in the US this year
▼ + stars: | 2023-07-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +12 min

It was shown in May and in fuller Phase 3 clinical trial results released at the Alzheimer’s Association International Conference on Monday to delay the disease’s progression. More than 6 million Americans are estimated to have Alzheimer’s disease, with about 1 million estimated to be in the early symptomatic stages where these drugs have shown benefit. Both Leqembi and donanemab work by clearing buildups of a protein in the brain called amyloid, a hallmark of Alzheimer’s. It’s been a hypothesis that treating Alzheimer’s earlier with amyloid-clearing drugs would yield better results; Skovronsky said the donanemab trial bore that out. “We could look at people who had mild cognitive impairment, MCI, which is the earliest stage, versus mild Alzheimer’s versus moderate Alzheimer’s,” Skovronsky explained.

Persons: Leqembi, Eli Lilly’s donanemab, Lilly, “ Donanemab, Jennifer Manly, Kacie, ”, Dr, Gil Rabinovici, Renaud La Joie, Daniel Skovronsky, “, Skovronsky, ” Skovronsky, It’s, Eric Widera, Sharon Brangman, University of Wisconsin’s Dr, Nathaniel Chin, Donanemab, Lilly hasn’t, Lawrence Honig, Honig, White, Sanjay Gupta, Deters, ” Lilly, it’s “, it’s, there’s, Joe Montminy Organizations: CNN, Alzheimer’s Association, Food and Drug Administration, American Medical Association, Columbia University Irving Medical Center, University of California, MCI, SUNY, University of Wisconsin’s, Leqembi, FDA, donanemab, CNN Health, ” Manly Locations: Los Angeles, “

As yet another Alzheimer's drug targeting plaque buildup in the brain fails to improve cognition in patients, leading scientists said a significant shift is underway in the search for effective treatments for the disease. By 2050, that number is projected to rise to nearly 13 million, according to an estimate from the Alzheimer’s Association. Alzheimer’s disease is often referred to as “Type 3 diabetes,” a brain-specific form of diabetes that is the result of the brain’s neurons lacking glucose, said John Didsbury, the CEO of T3D Therapeutics. Data from the longest-ever phase 3 trial of exercise on cognition released at the conference on Tuesday found that exercise may stall cognitive decline in Alzheimer’s patients. He said it’s only a matter of time before we see more research discoveries that show potential for slowing Alzheimer’s disease, possibly within the next year or two.

Search resuls for: "Alzheimer’s Association International Conference"

13 mentions found